Wow. What a start to the week. In terms of news there was not much but we had an incredible flash crash in the large caps at the open. From a technical perspective, I do not know if this signals an end or what but there were some great long term bargains that I missed […]
August 4 Biotech Update
Looks like the sector was saving the fireworks for today with a lot more news. The reaction so far seems a little tepid given the positives but it is early and I think some are a little worried about the broader market. The collapse in oil may unfortunately signal a return to the macro market […]
July 27 Biotech Update
The market looks bad and it is bringing down the sector although I think BIIB has done a pretty good job at reversing some bullish biotech sentiment. That being said the sector might be outperforming the broader market a little as there was a nice big deal announced this morning. When all is said and […]
July 7 Biotech Update
There is a little more news today but still relatively quiet. The market seems to be looking for a direction but the sector seems to be outperforming to the upside. Yesterday was certainly better than expected but it also did not end in an exceptionally bullish manner. That is why I still think the market […]
November 17 Biotech Update
This morning was just a little bit busy. The market was neutral, which gives us a nice clean way to see how the biotechs are reacting to news. In general, it appears that good news is still moving stocks higher, although some of the moves were more muted than you would expect. In any case, […]
November 12 Biotech Update
A weaker start to the day today but I still see this as the market treading water as opposed to a new trend. I certainly would keep an eye on the action of the small caps as they have been an early warning signal and they too seem to be treading water with some winners […]
May 28 Biotech Update
Of course, there was a storm last night that knocked out the entire internet connection at LSU, so this is going to be later than usual and I have not been able to follow the market at all. I am getting this posted by hook and crook and hope to be back to normal tomorrow. […]
May 27 Biotech Update
It was a good start to the week with some notable underperformers. Not a lot of news but the sector seemed to be performing well, which is in line with the broader market. It does seem, however, that a number of small caps were getting a nice bid and outperforming which is something we have […]
May 23 Biotech Update
I expect today is going to slow dramatically as people get ready for the long weekend. As such, I want to get this out as early as possible to catch everyone. That being said there are a couple of things I want to touch on before the weekend. 1. How times for changed for GILD […]
April 22- Building Some Momentum
Everyone loves biotechs again. Has the bottom been put in? Perhaps but there was a lot of damage done to the sector, so I would remain selective on buys and not chase any of these early moves. That being said the coast is likely clear for the near term assuming that the large cap biotechs […]
Jan 8 Biotech Update- Looking to Europe for Value and Some Deals at Home
Well, it seemed like yesterday was the day of good data and today was the day of buyouts, what will tomorrow bring? The day of partnerships or the calm before the storm or something completely different? Regardless, two days of good news in the sector gave us a strong morning move that held up well […]
PSDV ALIM – Analysis of Iluvien for DME
On Thursday, Alimera (ALIM) and Psivida (PSDV) are expected to hear from the FDA on the status of their new drug application(NDA) for Iluvien(fluocinolone acetonide intravitreal implant) to treat chronic diabetic macular edema. With it’s third attempt, one could say Iluvien has taken the long and winding road to approval. The PDUFA date is October […]
May 29- EOD
It seemed like a nice selloff in biotech today. There were the occasional winners (INFI) but for the most part it was a sea of red today. The summer months can be difficult times for biotechs but they have been quite resilient and these sell-offs have ended up being good buying opportunities. 1. I want […]
Notes from JP Morgan Healthcare Conference (Monday/Tuesday session)
As we go into the 3rd day of the JP Morgan Healthcare Conference, we wanted to provide some highlights and notes from the first 2 sessions. I tried to keep them as concise as possible. Day 1 Clearly, Celgene Corp.(NASDAQ: CELG) came firing out of the gates by announcing strong financial guidance. This included in-line […]
DEPO – Quick Update – Paragraph IV – DM1992 Phase 2
Depomed released a statement that Actavis Group, a generic drug manufacturer filed a paragraph IV challenge against Gralise, Depomed’s once-daily gabapentin formulation. NEUTRAL on Paragraph IV We view this event as having no net impact. Patent challenges are not unexpected in this pharmaceutical environment, especially in the drug delivery space. The current generic drug legislation rewards early […]
